Plazza has raised $15 million in funding in its Series A round. This funding round was co-led by global top VC companies Accel, Elevation Capital, and Nexus Venture Partners. Existing investors All In Capital and Better Capital also supported the round. These fresh funds will specifically be allocated to strengthening the firm’s core technology platform. It will enhance its AI-powered inventory and assortment intelligence, scale its total operational capability, and grow its chain of pharmacies across new geographical areas.

Inventory footprint and founding vision

Plazza has a quick commerce application that delivers medicines as a first mover in order to maintain medicine availability on a timely basis. It is a pharmacy-first quick commerce platform. This is the company’s $15 million Series A funding round just 10 months after All In Capital led a $1.4 million seed round for Plazza. 

The earlier round was also led by Better Capital and Tracxn founder Abhishek Goyal, Vivekananda Hallekere, Singhania family office, and JK Tyre’s promoters. Plazza uses AI technologies for inventory management to ensure fast delivery of medicines to customers within a narrow timeframe of 15 to 30 minutes.

Plazza is filling a significant structural void that exists in the Indian pharmaceutical retail market, where the medical shops located in the neighborhood are selling an average of 5,000 medicines out of the total market worth more than 100,000 SKUs. To address this fulfillment challenge, Plazza store-level inventories exceed 40,000 SKUs, which is approximately 8 times the amount of inventory typically found within a conventional local pharmacy. This vast product presence allows Plazza to serve a prescription fill rate of over 95% in stark contrast to industry averages of 50–60%.

Financial metrics and competitive landscape

The vision of the company has brought about impressive growth statistics. As per the startup, gross merchandise value (GMV) grew by almost 27 times from June 2025 to March 2026. Metrics of customer retention show high customer engagement, offering approximately 30% larger order baskets for repeat visitors versus first-time visitors. Plazza is continuing to build ascending order volumes while maintaining its existing customer base with AI-driven assortment intelligence.

The Series A funding round reflects the growing competition in the instant medicine delivery space. Platforms like Flipkart and Zepto have attacked the market aggressively, with the former announcing entry via its Flipkart Minutes in December 2024 and the latter’s pharmacy service going on trial in 10 cities in 2025 with 10-minute deliveries. 

Beyond OTC drugs, Blinkit has also ventured into the prescription medicine delivery space in Bengaluru. The overall rapidly expanding pharmacy sector remains attracting significant investor interest, with previous pharmacy rounds led by investment firms Stellaris Venture Partners on the Bengaluru capex side raising $6 million in September 2025 and Accel and Peak XV Partners leading the $85 million round involving TrueMeds.

Conclusion

The successful $15 million raised by Plazza continues a trend of increased investor confidence in specialized quick-commerce platforms that aim to address the conceptual supply chain. The startup’s delivery promise of 15 to 30 minutes, combined with its ability to predict product needs with the help of AI and its vast inventory, has the potential to address the long-standing problem of drug stock availability in India. Plazza’s emphasis will be on commanding high fill rates and having strong pharmaceutical offers as others such as Flipkart, Zepto, and Blinkit ramp up their presence in the country.